
Medicamen Organics was incorporated on March 15, 1995. The company is engaged in the development, manufacturing, and distribution of a broad range of pharmaceutical dosage forms, including generic tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. It serves government (including both state and central governments) and private institutions as a contract manufacturer / third-party manufacturer.
| Bidding Dates |
|---|
| 21 Jun 2024 - 25 Jun 2024 |
| Subscription |
|---|
| 916.79x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹128,000 | 1 | 1 | 4000 | 3.1 M | ₹32 - ₹34 | 59.69 % | ₹99.2 M - ₹105.4 M | RHP DOC |
Medicamen Organics IPO SUBSCRIPTION STATUS
25 Jun '24Medicamen Organics IPO overall subscription rate was 916.79 times the total available shares
Medicamen Organics IPO retail subscription rate was 1729.76 times in the retail segment
Medicamen Organics IPO non-institutional investor subscription rate was 1772.95 times in the non-institutional investor category
Medicamen Organics IPO Qualified Institutional Bidder subscription rate was 90.87 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
25 Jun 2024 (Day 3) | 1729.76x | 1772.95x | 90.87x |
24 Jun 2024 (Day 2) | 448.61x | 164.94x | 0.74x |
21 Jun 2024 (Day 1) | 95.42x | 43.93x | 0.53x |
Medicamen Organics FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| FY24 | 24.0 | 252.7 | -36.9 | -40.3 | 18.8% |
| FY23 | 9.6 | 221.5 | -5.8 | -8.7 | 12.1% |
| FY22 | 1.0 | 209.8 | 0.4 | -5.8 | 6.7% |
Medicamen Organics IPO SUBSCRIPTION STATUS DETAILS
Medicamen Organics had 3.1 M shares on offer
Medicamen Organics IPO offer price was in the range ₹32 - ₹34
Medicamen Organics IPO minimum Investment was ₹128000
Medicamen Organics IPO issue size was ₹ 99.2 M - ₹ 105.4 M
Medicamen Organics had a minimum lot size of 4000 Shares per application
Medicamen Organics NUMBER OF SHARES ON OFFER
Medicamen Organics IPO IMPORTANT DATES
| Issue Open Date | 21 Jun 2024 |
| Issue close Date | 25 Jun 2024 |
| Allotment Date | 26 Jun 2024 |
| Refund Date | 26 Jun 2024 |
| Demat Account Credit Date | 27 Jun 2024 |
| Listing Date | 28 Jun 2024 |
| Listing on Exchange(s) | NSE |
| Medicamen Organics Allotment Status | Exchange |
Medicamen Organics IPO subscription opened on 21 Jun 2024, and closed on 25 Jun 2024
IPO allotment for Medicamen Organics was finalized on Wednesday, 26 Jun 2024
IPO listing for Medicamen Organics was on NSE on Friday, 28 Jun 2024
Medicamen Organics IPO LISTING GAINS
| Issue Price (adjusted) | 34.0 |
| Listing Open Price | 137.8 |
| Listing Close Price | 144.7 |
| Listing Gain% | 305.4% |
| Current Gain% | -34.7% |
Medicamen Organics Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicamen Organics Ltd. | 22.2 | 26 | -8.8 | 0.1 | 1.1 | -14 | -7.8 | 22.7 | -40.7 | -4 | -199.3 | -2.5 | -173.2 |
| Sun Pharmaceutical Industries Ltd. | 1884.9 | 452250.7 | 41.2 | 8.3 | 7.3 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 45.7 | 4.9 |
| Divi's Laboratories Ltd. | 11180.5 | 296807.2 | 88.3 | 2.5 | 24.3 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 126.7 | 35.3 |
| Torrent Pharmaceuticals Ltd. | 4689.5 | 178373.5 | 84 | -112.3 | 10.3 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 55.8 | -0.7 |
| Laurus Labs Ltd. | 2294.6 | 123980 | 92.5 | 1 | 15.8 | 16.8 | 8.4 | 6861.3 | 22.2 | 888.8 | 148 | 24.8 | 95.9 |
| Zydus Lifesciences Ltd. | 1200 | 120748.1 | 28.9 | -1.9 | 4 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 41.6 | -15 |
Medicamen Organics INFORMATION ON IPO ISSUE
About Medicamen Organics
Medicamen Organics was incorporated on March 15, 1995. The company is engaged in the development, manufacturing, and distribution of a broad range of pharmaceutical dosage forms, including generic tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. It serves government (including both state and central governments) and private institutions as a contract manufacturer / third-party manufacturer.
Object of the Issue
- Funding of expenses proposed to be incurred towards product registration in the international markets
- Plant updation and increase in production capacity
- Funding working capital requirements of the company
- General corporate purposes
Medicamen Organics - PROMOTERS
| Name |
|---|
| Bal Kishan Gupta |
Medicamen Organics Lead Manager of the Issue
GYR Capital Advisors Private Limited
info@gyrcapitaladvisors.com
Medicamen Organics Registrar to the issue
Kfin Technologies Private Limited
nvl.ipo@kfintech.com
Medicamen Organics Strengths
Wide range of products
The company's product portfolio consists of 84 products. It operates under different brand names across the globe. Its business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry
Scalable business model
The company's business model is customer-centric and order-driven, requiring optimal utilization of existing resources to ensure quality supply and achieve economies of scale
Quality assurance
The company has been approved by WHO GMP since September 21, 2011, for Manufacturing Facility 1 and July 11, 2018, for Manufacturing Facility 2. It has also obtained ISO 9001:2015 certification for the Quality Management System from ISC
Medicamen Organics Risks
Dependent on few customers
The company is dependent on a few customers for sales. Loss of any of these large customers may affect the revenues and profitability
Litigation and claims
The company, its directors, and its promoters are parties to certain litigation and claims. These legal proceedings are pending at various levels of adjudication before different forums and regulatory authorities. Any adverse decision may result in liabilities or penalties and could adversely affect the business
IPO FAQs
The promoter of the company is Bal Kishan Gupta.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 32.0 - 34.0.
The IPO application opens on Jun 21, 2024 and closes on Jun 25, 2024.
The minimum lot size for the IPO is 4000. The maximum lot size for the IPO is 4000.
For all category investors, the minimum application amount for this IPO is Rs. 128,000.0, the maximum value for this IPO is Rs 136,000.0.
This IPO will be allotted on Jun 26, 2024.
The refund will be credited to your account on Jun 26, 2024.
The allotted shares will be credited to your demat on Jun 27, 2024.
Medicamen Organics Ltd.’s shares listed on the stock exchanges on Jun 28, 2024.
